ArticleFrontiers in medicine2025
Oral high-dose sertraline-induced acute pancreatitis: a case report and literature review.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute pancreatitis (AP) is characterized by acute inflammation and pancreatic injury, with gallstones and chronic alcohol use representing the most common etiologies. Although drug-induced pancreatitis (DIP) accounts for fewer than 3% of AP cases, its recognition as a significant contributor to AP is growing. Sertraline, a widely prescribed selective serotonin reuptake inhibitor (SSRI), is associated with diverse adverse effects, even at therapeutic doses. We present a case of a 27-year-old female with a history of depression who developed mild acute pancreatitis following a sertraline overdose. Diagnostic evaluation, including computed tomography (CT) and serological analysis, revealed pancreatic parenchymal swelling and elevated serum amylase levels, confirming AP. Other potential causes were systematically excluded. The patient's condition resolved following drug discontinuation and standard supportive therapy. This case underscores the need for heightened clinical awareness of SSRI-associated pancreatitis, particularly in the context of overdose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.